Srinagar Magazine

CD BioSciences Unveils Updated Comprehensive Bioanalytical Testing Services for Drug Development

 Breaking News
  • No posts were found

CD BioSciences Unveils Updated Comprehensive Bioanalytical Testing Services for Drug Development

August 20
21:56 2020
To advance the clinical trial development of worldwide clients, CD BioSciences now introduces its optimized one-stop bioanalytical testing services, covering biomarker, anti-drug antibody, pharmacokinetics, toxicokenetics assays, etc.

New York, USA – August 20, 2020 – According to statistics, between 2009 and 2018, the average cost of discovery and development of a new drug is $1.3 billion and it may take approximately 10 years for the drug to reach the market. To test if it’s a safe and efficacious drug, the emergence of the field of bioanalysis as a critical tool during the drug development process is well understood and globally accepted.

With over 10 years’ scientific experience, CD BioSciences has been a global leader in bioanalytical testing solutions. The comprehensive bioanalytical lab testing services are based on advanced laboratory facilities and a scientific team of experienced laboratory experts, aiming at facilitating clients’ non-clinical and clinical drug development programs across all phases of pharmaceutical development and commercialization.

The state-of-art array of bioanalytical assays includes but is not limited to:

• Method Development, Feasibility and Validation
• Non-GLP Sample Analysis
• Pharmacokinetic (PK) and Toxicokinetic (TK) Analysis
• Drug Discovery
• Drug-drug Interaction Studies
• High-Throughput In Vitro Screening Studies
• Clinical Study-compliance Samples
• Method Qualifications

The highlight features of bioanalytical testing services ensure the success of both clients’ programs and CD BioSciences. Firstly, hundreds of validated assays are available with extensive capabilities to handle complex bioanalytical testing services, and new assays are under design to best fit special requirements of clients (over 50 developed and validated methods each year). Secondly, comprehensive bioanalytical SOPs ensure full compliance with GLP and GCLP standards, as well as other regulatory guidance. Thirdly, efficient procedures and methods will deliver high-quality data with a fast turn-around time from receipt of sample to data delivery.

“We have completed many drug development programs from bioanalytical testing services to clinical trial operations. Based on these programs, our team has accumulated a deep understanding of regulatory guidelines, requirements,” introduced by a senior scientist at CD BioSciences, “with extensive experience and scientific knowledge, we are committed to helping our clients navigate and expedite the regulatory approval of your drug candidate.”

Detailed information about the services and case study can be found on https://www.cd-biosciences.com.

About CD BioSciences

Founded in 2004, and located in New York, CD BioSciences offer a full range of clinical trial consulting, design, conduction, management, reporting and analysis services to advance clinical trial development needs of global clients. The clinical trial services focus on the entire clinical trial lifecycle including bioanalytical lab testing, clinical pharmacology, first-in-human (FIH), proof of concept (POC), early phase trials, CDM analysis and reporting, and biostatistics services.

Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.cd-biosciences.com

Related Articles